Lexicon Pharmaceuticals
The company's clinical drug candidates include sotagliflozin ( LX4211 ) for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl ( LX1032 ) for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases , such as rheumatoid arthritis . 
<triplet> telotristat ethyl <subj> carcinoid syndrome <obj> medical condition treated <triplet> carcinoid syndrome <subj> telotristat ethyl <obj> drug used for treatment